A5057313307- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Bacteriophages and microbial interactions
- Infectious Diseases and Tuberculosis
- Monoclonal and Polyclonal Antibodies Research
- Neuroendocrine Tumor Research Advances
- Cancer Research and Treatments
- Orthopedic Infections and Treatments
- COVID-19 Clinical Research Studies
- Otolaryngology and Infectious Diseases
- COVID-19 Impact on Reproduction
- Colorectal and Anal Carcinomas
- Shoulder and Clavicle Injuries
- Rabies epidemiology and control
- Amoebic Infections and Treatments
- Immune cells in cancer
- Streptococcal Infections and Treatments
- Bacillus and Francisella bacterial research
- SARS-CoV-2 and COVID-19 Research
Inserm
2021-2022
Université de franche-comté
2021
Université de Bourgogne
2021
Observatoire des Sciences de l’Univers Terre Homme Environnement Temps Astronomie
2020
Hôpital des Diaconesses
1957
Convalescent plasma therapy has been described as an attractive approach to treat critically ill patients with COVID-19 (Coronavirus disease 2019). The selection of convalescent donors (CPD) is commonly based on neutralizing antibody titer. A better understanding the quality immune responses following will enable optimization donors' in programs. involvement SARS-CoV-2 specific T cells induction and persistence high affinity anti-SARS-CoV-2 still poorly investigated. In this study, 115 CPD...
The human leucine-rich repeat-containing protein 15 (LRRC15) is a membrane identified as marker of CAF (cancer-associated fibroblast) cells whose overexpression positively correlated with cancer grade and outcome. Nuclear molecular imaging (i.e., SPECT PET) to track LRRC15 expression could be very useful in guiding further therapeutic strategies. In this study, we developed an ScFv mouse phage-display library obtain small fragment antibodies against for purposes. Mice were immunized...
3044 Background: Increasing evidence highlights the crucial roles played by CD4+ Th1 cells in cancer immunity and immunotherapy (Spitzer et al., Cell 2017, Borst Nat rev Immunol 2018). Here, we investigate relevance of circulating CD4 response against shared tumor-associated antigens (TAA) patients treated anti-PD-1 immunotherapy. Methods: A total 46 advanced (pts) including 32 pts with non-small cell lung (NSCLC), 14 melanoma, were enrolled (ITHER trial NCT02840058). Patients therapy as...